Neurological adverse effects of methylphenidate may be misdiagnosed as meningoencephalitis

Area of Science:

• Neurology
• Pediatrics
• Pharmacology

Background:

• Methylphenidate is a central nervous system stimulant commonly prescribed for Attention Deficit and Hyperactivity Disorder (ADHD).
• While generally safe and effective, potential adverse effects require ongoing monitoring, especially in pediatric populations.

Observation:

• A 7-year-old boy developed new-onset ataxic gait, orofacial dyskinesias, and choreoathetosis. These symptoms emerged after initiating methylphenidate treatment for ADHD.
• Initial investigations including blood work, electroencephalogram (EEG), and CT scan of the head were unremarkable, ruling out other common causes.

Findings:

• A causal link was established between methylphenidate therapy and the patient's severe neurological symptoms.
• Discontinuation of methylphenidate resulted in a rapid and significant improvement in the observed neurological deficits.

Implications:

• This case highlights the importance of considering methylphenidate-induced movement disorders in children presenting with new-onset neurological symptoms.
• Clinicians should maintain a high index of suspicion for medication side effects and consider dose adjustment or discontinuation when such symptoms arise.
• Further research into the mechanisms and prevalence of methylphenidate-associated movement disorders is warranted.